Biomind Labs Inc.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more
Biomind Labs Inc. (BMNDF) - Total Liabilities
Latest total liabilities as of September 2025: $1.62 Million USD
Based on the latest financial reports, Biomind Labs Inc. (BMNDF) has total liabilities worth $1.62 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biomind Labs Inc. - Total Liabilities Trend (2015–2024)
This chart illustrates how Biomind Labs Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biomind Labs Inc. Competitors by Total Liabilities
The table below lists competitors of Biomind Labs Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advance Metals Ltd
AU:AVM
|
Australia | AU$379.29K |
|
Profoto Holding AB
ST:PRFO
|
Sweden | Skr453.00 Million |
|
RP Optical Lab Ltd
TA:RPOL
|
Israel | ₪14.82 Million |
|
Integrum AB Series B
ST:INTEG-B
|
Sweden | Skr22.09 Million |
|
ReVolve Renewable Power Corp.
OTCQB:REVVF
|
USA | $11.99 Million |
|
Burgundy Diamond Mines Ltd
AU:BDM
|
Australia | AU$723.12 Million |
|
Iris Business Services Limited
NSE:IRIS
|
India | ₹611.02 Million |
|
Netcare
JSE:NTC
|
South Africa | ZAC18.24 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Biomind Labs Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 28.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomind Labs Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomind Labs Inc. (2015–2024)
The table below shows the annual total liabilities of Biomind Labs Inc. from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.34 Million | -10.95% |
| 2023-12-31 | $1.51 Million | +347.35% |
| 2022-12-31 | $336.72K | +0.53% |
| 2021-12-31 | $334.95K | +441.70% |
| 2020-12-31 | $61.83K | +18.57% |
| 2019-12-31 | $52.15K | -79.87% |
| 2018-12-31 | $259.01K | +26.95% |
| 2017-12-31 | $204.03K | -1.35% |
| 2016-12-31 | $206.82K | -21.84% |
| 2015-12-31 | $264.60K | -- |